Cell-based Cancer Immunotherapy, Volume 183 provides the latest progress concerning research on anticancer cellular immunotherapies and their immunological, translation, or clinical aspects. Topics covered in this volume include Methods behind clinical DC vaccine products against glioblastoma, Fully closed and automated isolation of natural blood dendritic cells for cancer immunotherapy, Methods behind Oncolytic virus-based DC vaccines in cancer: towards a multiphase combined treatment strategy for Glioblastoma (GBM) patients, Identification of TCR repertoire patterns linked with anti-cancer immunotherapy, Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells, Methods behind neoantigen predictions for anticancer vaccines, Methods behind CD137L-DC-EBV-VAX anticancer vaccine, and much more.
Additional sections cover Gold Standard Assessment of Immunogenic Cell Death Induced by Photodynamic Therapy: From In Vitro to Tumor Mouse Models and Anti-Cancer Vaccination Strategies, Methods behind TCR analyses for colorectal cancer-associated TILs, The use of xCELLigence, Incucyte, and/or Cr/LDH/maker-release assays, Humanized mouse models for anti-cancer therapy, In vitro re-challenge of CAR T cells, Methods behind adoptively transferred tumor draining lymphocytes? for anticancer immunotherapy, and A murine glioblastoma platform to test cellular therapies with the standard of care.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Series Page - p. iii 5. Copyright - p. iii 6. Contributors - p. iii 7. Chapter 1: Generation and quality control of mature monocyte-derived dendritic cells for immunotherapy - p. 1 8. Chapter 2: Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy - p. 33 9. Chapter 3: Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients - p. 62 10. Chapter 4: Identification of TCR repertoire patterns linked with anti-cancer immunotherapy - p. 115 11. Chapter 5: Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells - p. 143 12. Chapter 6: Methods behind neoantigen prediction for personalized anticancer vaccines - p. 161 13. Chapter 7: Methods for generating the CD137L-DC-EBV-VAX anti-cancer vaccine - p. 187 14. Chapter 8: Gold standard assessment of immunogenic cell death induced by photodynamic therapy: From in vitro to tumor mouse models and anti-cancer vaccination strategies - p. 256 15. Chapter 9: Neoantigen identification: Technological advances and challenges - p. 265 16. Chapter 10: In vitro assays to evaluate CAR-T cell cytotoxicity - p. 303 17. Chapter 11: Humanized mouse models for anti-cancer therapy - p. 317 18. Chapter 12: In vitro re-challenge of CAR T cells - p. 335 19. Chapter 13: Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro - p. 355 20. Chapter 14: Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model - p. 381
Cell-based Cancer Immunotherapy, Volume 183 provides the latest progress concerning research on anticancer cellular immunotherapies and their immunological, translation, or clinical aspects. Topics covered in this volume include Methods behind clinical DC vaccine products against glioblastoma, Fully closed and automated isolation of natural blood dendritic cells for cancer immunotherapy, Methods behind Oncolytic virus-based DC vaccines in cancer: towards a multiphase combined treatment strategy for Glioblastoma (GBM) patients, Identification of TCR repertoire patterns linked with anti-cancer immunotherapy, Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells, Methods behind neoantigen predictions for anticancer vaccines, Methods behind CD137L-DC-EBV-VAX anticancer vaccine, and much more.
Additional sections cover Gold Standard Assessment of Immunogenic Cell Death Induced by Photodynamic Therapy: From In Vitro to Tumor Mouse Models and Anti-Cancer Vaccination Strategies, Methods behind TCR analyses for colorectal cancer-associated TILs, The use of xCELLigence, Incucyte, and/or Cr/LDH/maker-release assays, Humanized mouse models for anti-cancer therapy, In vitro re-challenge of CAR T cells, Methods behind adoptively transferred tumor draining lymphocytes? for anticancer immunotherapy, and A murine glioblastoma platform to test cellular therapies with the standard of care.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Series Page - p. iii 5. Copyright - p. iii 6. Contributors - p. iii 7. Chapter 1: Generation and quality control of mature monocyte-derived dendritic cells for immunotherapy - p. 1 8. Chapter 2: Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy - p. 33 9. Chapter 3: Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients - p. 62 10. Chapter 4: Identification of TCR repertoire patterns linked with anti-cancer immunotherapy - p. 115 11. Chapter 5: Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells - p. 143 12. Chapter 6: Methods behind neoantigen prediction for personalized anticancer vaccines - p. 161 13. Chapter 7: Methods for generating the CD137L-DC-EBV-VAX anti-cancer vaccine - p. 187 14. Chapter 8: Gold standard assessment of immunogenic cell death induced by photodynamic therapy: From in vitro to tumor mouse models and anti-cancer vaccination strategies - p. 256 15. Chapter 9: Neoantigen identification: Technological advances and challenges - p. 265 16. Chapter 10: In vitro assays to evaluate CAR-T cell cytotoxicity - p. 303 17. Chapter 11: Humanized mouse models for anti-cancer therapy - p. 317 18. Chapter 12: In vitro re-challenge of CAR T cells - p. 335 19. Chapter 13: Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro - p. 355 20. Chapter 14: Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model - p. 381
